PROSTATE CANCER SCREENING

Prostate cancer screening involves several matters that must be analyzed prior to its incorporation into clinical practice and as public health program. The expected benefit is the mortality reduction. The harms include false positives, anxiety associated with overdiagnosis and the damages of its overtreatment, which never will have evolved clinically. A bibliographic review was conducted during November 2015, through the databases Pubmed and Scielo, searching for articles between 2009 and 2015. Posteriorly, it was organized a round table event was organized an event: Roundtable on FAMINAS –BH, with the theme "Prostate Cancer - screening or not in Primary Care ", in which academicians and specialists in Urology and Family and Community Medicine have participated in order to promote a discussion regarding the screening for prostate cancer considering that this subject has divergent approaches among different medical societies. As a result of this work, Family Doctors argued based in an American study, with 11 years of monitoring, that PSA plus rectal touch has not reduced patients mortality. Thus, they consider that PSA plus rectal touch is not included as a screening modality. Moreover, urologists positioned themselves in favor of the screening based in an European study that presented 20% reduction in mortality in patients submitted to screening for 9 years. They also support that the current recommendation is to follow individualized protocols for each patient. Therefore, it has been noted the importance of medical practice based on evidence both in Primary Health but also for future professionals.